Advances in the diagnosis and classification of systemic lupus erythematosus

References

• Bertsias GK, Pamfil C, Fanouriakis A, et al. Diagnostic criteria for systemic lupus erythematosus: has the time come? Nat Rev Rheumatol. 2013;9:687–694.
   PubMed Web of Science ®Google Scholar
• Cohen AS, Reynolds WE, Franklin EC, et al. Preliminary criteria for the classification of systemic lupus erythematosus. Bull Rheum Dis. 1971;21:643–648.
   Google Scholar
• Doria A, Zen M, Canova M, et al. SLE diagnosis and treatment: when early is early. Autoimmun Rev. 2010;10:55–60.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Ringold S, Khanna D, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res (Hoboken). 2015;67:891–897.
   PubMed Web of Science ®Google Scholar
• Pons-Estel GJ, Wojdyla D, McGwin G Jr, et al. The American College of Rheumatology and the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus in two multiethnic cohorts: a commentary. Lupus. 2014;23:3–9.
   PubMed Web of Science ®Google Scholar
• June RR, Aggarwal R. The use and abuse of diagnostic/classification criteria. Best Pract Res Clin Rheumatol. 2014;28:921–934.
   PubMed Web of Science ®Google Scholar
• Petri M, Orbai AM, Alarcòn GS, et al. Derivation and validation of the systemic lupus in- ternational collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677–2686.
   PubMed Web of Science ®Google Scholar
• Fries JF, Siegel RC. Testing the “preliminary criteria for classification of SLE”. Anna RheumDis. 1973;32:171–177.
   PubMed Web of Science ®Google Scholar
• Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271–1277.
   PubMed Web of Science ®Google Scholar
• Cervera R, Espinosa G. Connective tissue diseases: classification criteria for SLE: the latest-but not least-attempt. Nat Rev Rheumatol. 2012;8:506–507.
   PubMed Web of Science ®Google Scholar
• Petri M. Review of classification criteria for systemic lupus erythematosus. RheumDisClin North Am. 2005;31:245–254.
   PubMed Web of Science ®Google Scholar
• Petri M, Magder L. Classification criteria for systemic lupus erythematosus: a review. Lupus. 2004;13:829–837.
   PubMed Web of Science ®Google Scholar
• Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
   PubMed Web of Science ®Google Scholar
• Yu C, Gershwin ME, Chang C. Diagnostic criteria for systemic lupus erythematosus: a critical review. J Autoimmun. 2014;48–49:10–13.
   PubMed Web of Science ®Google Scholar
• Inês L, Silva C, Galindo M, et al. Classification of Systemic Lupus Erythematosus: SystemicLupus International Collaborating Clinics versus American College of Rheumatology Criteria. A comparative Study of 2,055 patients from a real-life, international systemic lupus eryhtematosus cohort. Arthritis Care Res (Hoboken). 2015;67:1180–1185.
   PubMed Web of Science ®Google Scholar
• Alarcon GS, McGwin G, Madger L, et al. Comparing the ACR and the SLICC criteria for the classification of SLE patients using data from an existing multi-ethnic cohort. Arthritis Rheum. 2012;64:S262.
   Web of Science ®Google Scholar
• Alarcon GS, Friedman AW, Straaton KV, et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. Lupus in Minority populations; Nature vs. Nurture. Lupus. 1999;8:197–209.
   PubMed Web of Science ®Google Scholar
• Schneider M, Lang MH. SLE classification: plus ça change, plus c’est la même chose. Nature Rev. 2015;11:262–264.
   Web of Science ®Google Scholar
• Mosca M, Bombardieri S. Disease-specific quality indicators, guidelines, and outcome measures in systemic lupus erythematosus (SLE). Clin Exp Rheumatol. 2007;25:107–113.
   PubMed Web of Science ®Google Scholar
• Olsen NJ, Karp DR. Autoantibodies and SLE: the threshold for disease. Nat Rev Rheumatol. 2014;10:181–186.
   PubMed Web of Science ®Google Scholar
• Robertson JM, James JA. Preclinical systemic lupus erythematosus. Rheum Dis Clin North Am. 2014;40:621–635.
   PubMed Web of Science ®Google Scholar
• Doria A, Mosca M, Gambari PF, et al. Defining unclassifiable connective tissue diseases: incomplete, undifferentiated, or both? J Rheumatol. 2005;32:213–215.
   PubMed Web of Science ®Google Scholar
• Bourn R, James JA. Preclinical lupus. CurrOpinRheumatol. 2015;27:433–439.
   Google Scholar
• Fabio G, Carrabba M, Hu C, et al. Dramatic development of severe SLE in a patient with an incomplete disease. RheumatolInt. 2005;25:543–547.
   Web of Science ®Google Scholar
• Grönhagen CM, Nyberg F. Cutaneous lupus erythematosus: an update. Indian Dermatol Online J. 2014;5:7–13.
   PubMedGoogle Scholar
• Calvo-Alen J, Alarcon GS, Burgard SL, et al. Systemic lupus erythematosus: predictors of its occurrence among a cohort of patients with early undifferentiated connective tis- sue disease: multivariate analyses and identification of risk factors. J Rheumatol. 1996;23:469–475.
   PubMed Web of Science ®Google Scholar
• Al Daabil M, Massarotti EM, Fine A, et al. Development of SLE among ‘potential SLE’ patients seen in consultation: long-term follow-up. Int J Clin Pract. 2014;68:1508–1513.
   PubMed Web of Science ®Google Scholar
• Grönhagen CM, Gunnarsson I, Svenungsson E, et al. Cutaneous manifestations and serological findings in 260 patients with systemic lupus erythematosus. Lupus. 2010;19:1187–1194.
   PubMed Web of Science ®Google Scholar
• Amezcua-Guerra LM, Higuera-Ortiz V, Arteaga-Garcìa U, et al. Performance of the 2012 Systemic Lupus International Collaborating Clinics and the 1997 American College of Rheumatology Classification Criteria for Systemic lupus Erythematosus in a Real-Life Scenario. Arthritis Care Res. 2015;67:437–441.
   PubMed Web of Science ®Google Scholar
• Hanly JG, O’Keeffe AG, Su L, et al. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016;55:2522–2562.
   Web of Science ®Google Scholar
• Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64:797–808.
   PubMed Web of Science ®Google Scholar
• Bose B, Silverman ED, Bargman JM. Ten common mistakes in the management of lupus nephritis. Am J Kidney Dis. 2014;63:667–676.
   PubMed Web of Science ®Google Scholar
• Weening JJ, D’Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521–530.
   PubMed Web of Science ®Google Scholar
• Giannakakis K, Faraggiana T. Histopathology of lupus nephritis. Clinic Rev Allerg Immunol. 2011;40:170–180.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Parikh S, Alvarado A. The kidney biopsy in lupus nephritis: is it still relevant? Rheum Dis Clin North Am. 2014;40:537–552.
   PubMed Web of Science ®Google Scholar
• Corwin HL, Schwartz MM, Lewis EJ. The importance of sample size in the interpretation of the renal biopsy. Am J Nephrol. 1988;8:85–89.
   PubMed Web of Science ®Google Scholar
• Giannico G, Fogo AB. Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis? Clin J Am Soc Nephrol. 2013;8:138–145.
   PubMed Web of Science ®Google Scholar
• De Rosa M, Toblii J, De Rosa G, et al. Could proteinuria less than 500mg/d be an actual indicator of lupus nephritis biopsy? J Am SocNephrol. 2013. Annual Meeting Abstracts: P0720.
   Google Scholar
• Peterson KS, Huang JF, Zhu J, et al. Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest. 2004;113:1722–1733.
   PubMed Web of Science ®Google Scholar
• Liu CC, Ahearn JM. The search for lupus biomarkers. Best Pract Res Clin Rheumatol. 2009;23:507–523.
   PubMed Web of Science ®Google Scholar
• Mayeux R. Biomarkers: potential uses and limitations. NeuroRx. 2004;1:182–188.
   PubMedGoogle Scholar
• Illei GG, Tackey E, Lapteva L, et al. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum. 2004;50:1709–1720.
   PubMed Web of Science ®Google Scholar
• Arbuckle MR, Mc Clain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526–1533.
   PubMed Web of Science ®Google Scholar
• Lyons R, Narain S, Nichols C, et al. Effective use of autoantibody tests in the diagnosis of systemic autoimmune disease. Ann NY Acad Sci. 2005;1050:217–228.
   PubMed Web of Science ®Google Scholar
• Emlen W, O’Neill L. Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum. 1997;40:1612–1618.
   PubMed Web of Science ®Google Scholar
• Oke V, Wahren-Herlenius M. Cutaneous lupus erythematosus: clinical aspects and molecular pathogenesis. J Intern Med. 2013;273:544–554.
   PubMed Web of Science ®Google Scholar
• Tan EM, Feltkamp TE, Smolen JS, et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum. 1997;40:1601–1611.
   PubMed Web of Science ®Google Scholar
• Slater CA, Davis RB, Shmerling RH. Antinuclear antibody testing. Arch Intern Med. 1996;156:1421–1425.
   PubMed Web of Science ®Google Scholar
• Mariz HA, Sato E, Barbosa SH, et al. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum. 2011;63:191–200.
   PubMed Web of Science ®Google Scholar
• Kumar Y, Bhatia A, Minz RW. Antinuclear antibodies and their detection methods in diagnosis of connective tissue diseases: a journey revisited. Diagnostic Pathology. 2009;4:1.
   PubMed Web of Science ®Google Scholar
• Wichainun R, Kasitanon N, Wangkaew S, et al. Sensitivity and specificity of ANA and anti-dsDNA in the diagnosis of systemic lupus erythematosus: a comparison using control sera obtained from healthy individuals and patients with multiple medical problems. Asian Pac J Allergy Immunol. 2013;31:292–298.
   PubMed Web of Science ®Google Scholar
• Pan LT, Tin SK, Boey ML, et al. The sensitivity and specificity of autoantibodies to the Sm antigen in the diagnosis of systemic lupus erythematosus. Ann Acad Med Singapore. 1998;27:21–23.
   PubMedGoogle Scholar
• Carmona-Fernandes D, Santos MJ, Canhão H, et al. Anti-ribosomal P protein IgG autoantibodies in patients with systemic lupus erythematosus: diagnostic performance and clinical profile. BMC Medicine. 2013;11:98.
   PubMed Web of Science ®Google Scholar
• Pisetsky DS. Anti-DNA antibodies-quintessential biomarkers of SLE. Nat Rev Rheumatol. 2016;12:102–110.
   PubMed Web of Science ®Google Scholar
• Aggarwal A. Role of autoantibody testing. Best Pract Res ClinRheumatol. 2014;28:907–920.
   PubMed Web of Science ®Google Scholar
• Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358:929–939.
   PubMed Web of Science ®Google Scholar
• Gualtierotti R, Biggioggero M, Penatti AE, et al. Updating on the pathogenesis of systemic lupus erythematosus. Autoimmun Rev. 2010;10:3–7.
   PubMed Web of Science ®Google Scholar
• Reveille JD. Predictive value of autoantibodies for activity of systemic lupus erythematous. Lupus. 2004;13:290–297.
   PubMed Web of Science ®Google Scholar
• Agmon-Levin N, Mosca M, Petri M, et al. Systemic lupus erythematosus one disease or many? AutoimmunityReviews. 2012;11:593–595.
   Web of Science ®Google Scholar
• Rekvig OP. Anti-dsDNA antibodies as a classification criterion and a diagnostic marker for systemic lupus erythematosus: critical remarks. Clin Exp Immunol. 2015;179:5–10.
   PubMed Web of Science ®Google Scholar
• Kurien BT, Scofield RH. Autoantibody determination in the diagnosis of systemic lupus erythematosus. Stand J Immunol. 2006;64:227–235.
   PubMed Web of Science ®Google Scholar
• Compagno M, Jacobsen S, Rekvig OP, et al. Low diagnostic and predictive value of anti-dsDNA antibodies in unselected patients with recent onset of rheumatic symptoms: results from a long-term follow-up Scandinavian multicentre study. Scand J Rheumatol. 2013;42:311–316.
   PubMed Web of Science ®Google Scholar
• Assess S, Mohan C. Biomarkers in rheumatic diseases: how can they facilitate diagnosis and assessment of disease activity? BMJ. 2015;351:h5079.
   PubMed Web of Science ®Google Scholar
• Zieve GW, Khusial PR. The anti-Sm immune response in autoimmunity and cell biology. Autoimmun Rev. 2003;2:235–240.
   PubMed Web of Science ®Google Scholar
• Mahler M, Waka A, Hiepe F, et al. Effect of dsDNA binding to SmD-derived peptides on clinical accuracy in the diagnosis of systemic lupus erythematosus. Arthritis Res Ther. 2007;9:R68.
   PubMed Web of Science ®Google Scholar
• Mahler M. Sm peptides in differentiation of autoimmune diseases. Adv Clin Chem. 2011;54:109–128.
   PubMed Web of Science ®Google Scholar
• Eriksson C, Kokkonen H, Johannson M, et al. Autoantibodies predate the onset of systemic lupus erythematous in northern Sweden. Arthritis Res Ther. 2011;13:R30.
   PubMed Web of Science ®Google Scholar
• Homma M, Mimori T, Takeda Y, et al. Autoantibodies to the Sm antigen: immunological approach to clinical aspects of systemic lupus erythematous. J Rheumatol Suppl. 1987;14(Suppl 13):188–193.
   PubMedGoogle Scholar
• Ishizaki J, Saito K, Nawata M, et al. Low complements and high titre of anti-Sm antibody as predictors of histopatologically proven silent ups nephritis without abnormal urinalysis in patients with systemic lupus erythematous. Rheumatology (Oxford). 2015;54:405–412.
   PubMed Web of Science ®Google Scholar
• Ortega-Hernandez OD, Shoenfeld Y. Mixed connective tissue disease: an overview of clinical manifestations, diagnosis and treatment. Best Pract Res Clin Rheumatol. 2012;26:61–72.
   PubMed Web of Science ®Google Scholar
• Tani C, Carli L, Vagnani S, et al. The diagnosis and classification of mixed connective tissue disease. J Autoimmun. 2014;48–49:46–49.
   PubMed Web of Science ®Google Scholar
• Vlachoyiannopoulos PG, Guials A, Tzioufas G, et al. Predominance of IgM anti-U1RNP antibodies in patients with systemic lupus erythematosus. Br J Rheumatol. 1996;35:534–541.
   PubMedGoogle Scholar
• Hanly JG. New insights into central nervous system lupus: a clinical prospective. Curt Rheumatol Rep. 2007;9:116–124.
   PubMedGoogle Scholar
• Jeltsch-David H, Muller S. Neuropsychiatric system lupus erythematosus: pathogenesis and biomarkers. Nat Rev Neurol. 2014;10:579–596.
   PubMed Web of Science ®Google Scholar
• Hirohata S, Arinuma Y, Yanagida T, et al. Blood-brain barrier damages and intrathecal synthesis of anti-N-methyl-D-aspartate receptor NR2 antibodies in diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Arthritis Res Ther. 2014;16:R77.
   PubMed Web of Science ®Google Scholar
• Ghirardello A, Doria A, Zampieri S, et al. Anti-ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with IgG anticardiolipin antibodies. Ann Rheum Dis. 2000;59:975–981.
   PubMed Web of Science ®Google Scholar
• Mahler M, Kessenbrock K, Raats J, et al. Characterization of the human autoimmune response to the major C-terminal epitope of the ribosomal P proteins. J Mol Med. 2003;81:194–204.
   PubMed Web of Science ®Google Scholar
• Haddouk S, Marzouk S, Jallouli M, et al. Clinical and diagnostic value of ribosomal P autoantibodies in systemic lupus erythematosus. Rheumatology (Oxford). 2009;48:953–957.
   PubMed Web of Science ®Google Scholar
• Ghirardello A, Briani C, Lucchetta M, et al. Anti-ribosomal P protein antibodies and neuropsychiatric system lupus erythematosus: cross-sectional vs Prospective Studies. Lupus. 2010;19:771–773.
   PubMed Web of Science ®Google Scholar
• Karassa FB, Alfetra A, Ambrozic A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis of neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum. 2006;54:312–324.
   PubMed Web of Science ®Google Scholar
• Chi Z-R, Cao C-X, Tan G-Z, et al. The association of serum anti-ribosomal P antibody with clinical and serological disorders in systemic lupus erythematous: a systematic review and meta-analysis. Lupus. 2015;24:588–596.
   PubMed Web of Science ®Google Scholar
• Takeda I, Iwadate H, Sugisaki K, et al. Anti-ribosomal P antibodies are associated with nephritis, vascular thrombosis and lymphocytopenia in patients with systemic lupus erythematosus. Fukushima J Med Sci. 2005;51:11–18.
   PubMedGoogle Scholar
• Reichlin M, Wolfson-Reichlin M. Correlations of anti-dsDNA and anti-ribosomal P autoantibodies with lupus nephritis. Clin Immunol. 2003;108:69–72.
   PubMed Web of Science ®Google Scholar
• Quintana G, Coral-Alvarado P, Aroca G, et al. Single anti-P ribosomal antibodies are not associated with lupus nephritis in patients suffering from active systemic lupus erythematosus. Autoimmun Rev. 2010;9:750–755.
   PubMed Web of Science ®Google Scholar
• Hirohata S. Anti-ribosomal P antibodies and lupus nephritis. Clin Exp Nephrol. 2011;15:471–477.
   PubMed Web of Science ®Google Scholar
• Cook HT. Complement and kidney disease. Curr Opin Nephron Hypertens. 2013;22:295–301.
   PubMed Web of Science ®Google Scholar
• Leffler J, Bengtsson AA, Blom AM. The complement system in systemic lupus erythematosus: an update. Ann Rheum Dis. 2014;73:1601–1606.
   PubMed Web of Science ®Google Scholar
• Li H, Lin S, Yang S, et al. Diagnostic value of serum complement C3 and C4 levels in Chinese patients with systemic lupus erythematosus. Cain Rheumatol. 2015;34:471–477.
   PubMed Web of Science ®Google Scholar
• Nived O, Sturfelt G. ACR classification criteria for systemic lupus erythematosus: complement components. Lupus. 2004;13:877–879.
   PubMed Web of Science ®Google Scholar
• Macedo AC, Isaac L. Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway. Front Immune. 2016;7:55.
   PubMed Web of Science ®Google Scholar
• Ricklin D, Hajishengallis G, Yang K, et al. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785–797.
   PubMed Web of Science ®Google Scholar
• Su D, Liu R, Li X, et al. Possible novel biomarkers of organ involvement in systemic lupus erythematosus. Clin Rheumatol. 2014;33:1025–1031.
   PubMed Web of Science ®Google Scholar
• Thanei S, Vanhecke D, Trendelenburg M. Anti-C1q autoantibodies from systemic lupus erythematous patients activate the complement system via both the classical and lectin pathways. ClinImmunol. 2015;160:180–187.
   Google Scholar
• Holers VM. Anti-C1q autoantibodies amplify pathogenic complement activation in systemic lupus erythematosus. J Clin Invest. 2004;114:616–619.
   PubMed Web of Science ®Google Scholar
• Botto M, Walport MJ. C1q, autoimmunity and apoptosis. Immunobiology. 2002;205:395–406.
   PubMed Web of Science ®Google Scholar
• Robson MG, Walport MJ. Pathogenesis of systemic lupus erythematosus (SLE). ClinExp Allergy. 2001;31:678–685.
   Google Scholar
• Moroni G, Radice A, Giammarresi G, et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis. 2009;68:234–237.
   PubMed Web of Science ®Google Scholar
• Akhter E, Burlingame RW, Seaman AL, et al. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus. 2011;20:1267–1274.
   PubMed Web of Science ®Google Scholar
• Trendelenburg M, Lopez-Trascasa M, Potlukova E, et al. High prevalence of anti-C1q antibodies in biopsy proven active lupus nephritis. Nephrol Dial Transplant. 2006;21:3115–3121.
   PubMed Web of Science ®Google Scholar
• Yin Y, Wu X, Shan G, et al. Diagnostic value of serum anti-C1q antibodies in patients with lupus nephritis: a meta-analysis. Lupus. 2012;21:1088–1097.
   PubMed Web of Science ®Google Scholar
• Villalta D, Tozzoli R. Anti-Chromatin (Nucleosome) autoantibodies. In: Shoenfeld Y, Gershwin ME, Meroni PL, editors. Autoantibodies. 2nd ed. Amsterdam: Elsevier; 2006. p. 141–149.
   Google Scholar
• Ahearn JM, Liu CC, Kao AH, et al. Biomarkers for systemic lupus erythematosus. Transl Res. 2012;159:326–342.
   PubMed Web of Science ®Google Scholar
• Min DJ, Kim SJ, Park SH, et al. Anti-nucleosome antibody: significance in lupus patien- ts lacking anti-double-stranded DNA antibody. Clin Exp Rheumatol. 2002;20:13–18.
   PubMed Web of Science ®Google Scholar
• Bizzaro N, Villalta D, Giavarina D, et al. Are anti-nucleosome antibodies a better dia- gnostic marker than anti-dsDNA antibodies for systemic lupus erythematosus? A systematic review and a study of metanalysis. Autoimmun Rev. 2012;12:97–106.
   PubMed Web of Science ®Google Scholar
• Bigler C, Lopez-Trascasa M, Potlukova E, et al. Anti nucleosome antibodies as a marker of active proliferative lupus nephritis. Am J Kidney Dis. 2008;51:624–629.
   PubMed Web of Science ®Google Scholar
• Rekvig OP, van der Vlag J, Seredkina N. Review: antinucleosome antibodies: a critical reflection on their specificities and diagnostic impact. Arthritis Rheumatol. 2014;66:1061–1069.
   PubMed Web of Science ®Google Scholar
• De Giorgio LA, Konstantinov KN, Lee SC, et al. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nat Med. 2001;7:1189–1193.
   PubMed Web of Science ®Google Scholar
• Omdal R, Brokstad K, Waterloo K, et al. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol. 2005;12:392–398.
   PubMed Web of Science ®Google Scholar
• Arinuma Y, Yanagida T, Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. ArthritisRheum. 2008;58:1130–1135.
   PubMed Web of Science ®Google Scholar
• Yoshio T, Onda K, Nara H, et al. Association of IgG anti-NR2 glutamate receptor antibodies in cerebrospinal fluid with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2006;54:675–678.
   PubMed Web of Science ®Google Scholar
• Lauvsens MB, Omdal R. Systemic lupus erythematosus, the brain, and anti-NR2 antibodies. J Neurol. 2012;259:622–629.
   PubMed Web of Science ®Google Scholar
• Gono T, Kawaguchi Y, Kaneko H, et al. Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus. Rheumatology. 2011;50:1578–1585.
   PubMed Web of Science ®Google Scholar
• Manzi S, Navratil JS, Ruffing MJ, et al. Measurement of erythrocyte C4d and comple- ment receptor1 in the diagnosis of systemic lupus erythematosus. Arthritis Rheum. 2004;50:3596–3604.
   PubMed Web of Science ®Google Scholar
• Navratil JS, Manzi S, Kao AH, et al. Platelet C4d is highly specific for systemic lupus erythematosus. Arthritis Rheum. 2006;54:670–674.
   PubMed Web of Science ®Google Scholar
• Liu CC, Kao AH, Manzi S, et al. Biomarkers in systemic lupus erythematosus: challenges and prospects for the future. Ther Adv Muscoloskelet Dis. 2013;5:210–233.
   PubMedGoogle Scholar
• Liu CC, Manzi S, Ahearn JM. Anti lymphocyte autoantibodies generate T cell-C4d signatures in systemic lupus erythematosus. Transl Res. 2014;164:496–507.
   PubMed Web of Science ®Google Scholar
• Kalunian K, Chatham WW, Massarotti EM, et al. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus. Arthritis Rheum. 2012;64:4040–4047.
   PubMed Web of Science ®Google Scholar
• Adhya Z, Borozdenkova S, Karim MY. The role of cytokines as biomarkers in systemic lupus erythematosus and lupus nephritis. Nephrol Dial Transplant. 2011;26:3273–3280.
   PubMed Web of Science ®Google Scholar
• Liu CC, Manzi S, Kao AH, et al. Cell-bound complement biomarkers for SLE: from bench top to bedside. Rheum Dis Clin North Am. 2010;36:161–172.
   PubMed Web of Science ®Google Scholar
• Li Y, Fang X, Li QZ. Biomarker profiling for lupus nephritis. Genomics Proteomics Bioin- Formatics. 2013;11:158–165.
   PubMedGoogle Scholar
• Mok CC. Towards new avenues in the management of lupus glomerulonephritis. Nat Rev Rheumatol. 2016;12:221–234.
   PubMed Web of Science ®Google Scholar
• Susianti H, Iriane VM, Dharmanata S, et al. Analysis of urinary TGF-β1, MCP-1, NGAL, and IL-17 as biomarkers for lupus nephritis. Pathophysiology. 2015;22:65–71.
   PubMedGoogle Scholar
• Stypińska B, Paradowska-Gorycka A. Cytokines and microRNA as candidate biomarkers for systemic lupus erythematosus. Int J Mol. Sci. 2015;16:24194–24218.
   PubMed Web of Science ®Google Scholar
• Parikh SV, Malvar A, Song H, et al. Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders. Lupus Sci Med. 2015;2:e000112.
   Google Scholar
• Arriens C, Mohan C. Systemic lupus erythematosus diagnostics in the ‘omics’ era. Int J ClinRheumatol. 2013;8:671–687.
   Google Scholar